Rifaximin, a Poorly Absorbed Antibiotic: Pharmacology and Clinical Potential
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Rifaximin (4-deoxy-4′-methylpyrido[1′,2′-1,2]imidazo- [5,4-c]-rifamycin SV) is a synthetic antibiotic designed to modify the parent compound, rifamycin, in order to achieve low gastrointestinal (GI) absorption while retaining good antibacterial activity. Both experimental and clinical pharmacology clearly show that this compound is a nonsystemic antibiotic with a broad spectrum of antibacterial action covering Gram-positive and Gram-negative organisms, both aerobes and anaerobes. Being virtually nonabsorbed, its bioavailability within the GI tract is rather high with intraluminal and fecal drug concentrations that largely exceed the minimal inhibitory concentration values observed in vitro against a wide range of pathogenic organisms. The GI tract represents, therefore, the primary therapeutic target and GI infections the main indication. The appreciation of the pathogenic role of gut bacteria in several organic and functional GI diseases has increasingly broadened its clinical use, which is now extended to hepatic encephalopathy, small intestine bacterial overgrowth, inflammatory bowel disease and colonic diverticular disease. Potential indications include the irritable bowel syndrome and chronic constipation, Clostridium difficile infection and bowel preparation before colorectal surgery. Because of its antibacterial activity against the microorganism and the lack of strains with primary resistance, some preliminary studies have explored the rifaximin potential for Helicobacter pylori eradication. Oral administration of this drug, by getting rid of enteric bacteria, could also be employed to achieve selective bowel decontamination in acute pancreatitis, liver cirrhosis (thus preventing spontaneous bacterial peritonitis) and nonsteroidal anti-inflammatory drug (NSAID) use (lessening in that way NSAID enteropathy). This antibiotic has, therefore, little value outside the enteric area and this will minimize both antimicrobial resistance and systemic adverse events. Indeed, the drug proved to be safe in all patient populations, including young children. Although rifaximin has stood the test of time, it still attracts the attention of both basic scientists and clinicians. As a matter of fact, with the advancement of the knowledge on microbial-gut interactions in health and disease novel indications and new drug regimens are being explored. Besides widening the clinical use, the research on rifaximin is also focused on the synthesis of new derivatives and on the development of original formulations designed to expand the spectrum of its clinical use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Practice guidelines in acute pancreatitis
Banks, P. A., Freeman, M. L., & the Practice Parameters Committee of the American College of Gastroenterology (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00856.x · Cited by 2,050
Maternal Nutrition and Fetal Development
Bazer, F. W., Spencer, T. E., Wu, G., Cudd, T. A., & Meininger, C. J. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.9.2169 · Cited by 1,019
Dysbiosis in inflammatory bowel disease
Tamboli, C. P., Neut, C., Desreumaux, P., & Colombel, J. F. (2004) · Gut · doi:10.1136/gut.53.1.1 · Cited by 743
Small Intestinal Bacterial Overgrowth: A Framework for Understanding Irritable Bowel Syndrome
Lin, H. C. (2004) · JAMA · doi:10.1001/jama.292.7.852 · Cited by 396
Resistance of germfree rats to indomethacin-induced intestinal lesions
Robert, A., & Asano, T. (1977) · Prostaglandins · doi:10.1016/0090-6980(77)90178-2 · Cited by 312
Koebnick, C., Wagner, I., Leitzmann, P., Stern, U., & Zunft, H. F. (2003) · Canadian Journal of Gastroenterology · doi:10.1155/2003/654907 · Cited by 288
Linskens, R. K., Huijsdens, X. W., Savelkoul, P. H. M., Vandenbroucke-Grauls, C. M. J. E., & Meuwissen, S. G. M. (2001) · Scandinavian Journal of Gastroenterology · doi:10.1080/003655201753265082 · Cited by 233
Bouhnik, Y., Alain, S., Attar, A., Flourié, B., Raskine, L., Sanson-Le Pors, M. J., & Rambaud, J.-C. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01016.x · Cited by 199
Van felius, I. D., Akkermans, L. M. A., Bosscha, K., Verheem, A., Harmsen, W., Visser, M. R., & Gooszen, H. G. (2003) · Neurogastroenterology & Motility · doi:10.1046/j.1365-2982.2003.00410.x · Cited by 134
Cited by
Gatta, L., & Scarpignato, C. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13928 · Cited by 266
Self-citationDorrestein, P., Gentry, E., Collins, S., Panitchpakdi, M., Belda-Ferre, P., Stewart, A., Wang, M., Jarmusch, A., Avila-Pacheco, J., Plichta, D., et al. (2021) · doi:10.21203/rs.3.rs-820302/v1 · Cited by 197
Tandon, P., DeLisle, A., Topal, J. E., & Garcia–Tsao, G. (2012) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2012.08.017 · Cited by 158
Yang, J., Lee, H.-R., Low, K., Chatterjee, S., & Pimentel, M. (2008) · Digestive Diseases and Sciences · doi:10.1007/s10620-007-9839-8 · Cited by 129
Schoenfeld, P., Pimentel, M., Chang, L., Lembo, A., Chey, W. D., Yu, J., Paterson, C., Bortey, E., & Forbes, W. P. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12735 · Cited by 106
Metadata
- Authors
- Scarpignato, C., & Pelosini, I.
- Venue
- Chemotherapy
- Publisher
- S. Karger AG
- Published
- 2005
- Volume
- 51
- Issue
- Suppl. 1
- Pages
- 36-66
- ISSN
- 0009-3157 (ISSN-L)
- 1421-9794
- OpenAlex
- W2026317976
- Cited by
- 240
- References
- 9
- FWCI
- 6.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rifaximin, a Poorly Absorbed Antibiotic: Pharmacology and Clinical Potential. https://app.cochat.ai/papers/10.1159/000081990
- The paper
- Scarpignato, C., & Pelosini, I. (2005). Rifaximin, a Poorly Absorbed Antibiotic: Pharmacology and Clinical Potential. Chemotherapy. https://doi.org/10.1159/000081990
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.